CSF1R and neoplasm: Dovitinib (TKI258) is a small-molecule tyrosine kinase inhibitor targeting multiple RTKs, such as FGFRs [11], vascular endothelial growth factor receptor (VEGFR) [12], fetal liver tyrosine kinase receptor 3 (FLT-3) [13], and colony-stimulating factor receptor 1 (c-Fms) [14], which participates in tumor growth, survival, angiogenesis, and vascular development and is under clinical investigation in different malignancies [15].